BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Biogen, Inc. 

14 Cambridge Center

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-679-2000 Fax:


SEARCH JOBS


Industry
Biotechnology






 Company News
Biogen, Inc. And UCB, Inc. (UCBJF.PK) Enter Agreements To Commercialize Multiple Sclerosis And Hemophilia Therapies In Asia 1/30/2014 11:56:57 AM    More...
Biogen, Inc. Profit Rises As New Multiple Sclerosis Drug Shines 1/29/2014 7:51:00 AM    More...
Social Media Suggests an MS Dogfight Between Biogen, Inc. and Novartis AG (NVS) 5/24/2013 8:28:41 AM    More...
Biogen, Inc. Release: FAMPYRA(TM), the First Oral Treatment for the Improvement of Walking in MS, is Now Available in Canada 4/11/2012 9:46:17 AM    More...
Biogen, Inc. Takes Option to MAKScientific, LLC MS Program 3/15/2012 8:45:06 AM    More...
Biogen, Inc. Appoints Kenneth DiPietro Executive Vice President, Human Resources 1/30/2012 6:20:18 AM    More...
Biogen, Inc., and Elan Corporation PLC (ELN) Release: ASCEND Study to Evaluate the Effectiveness of TYSABRI® (natalizumab) as a Treatment for Secondary-Progressive Multiple Sclerosis 1/26/2012 7:16:11 AM    More...
Biogen, Inc. to Report Fourth Quarter & Year End 2011 Financial Results on January 31, 2012 1/17/2012 5:52:36 AM    More...
Biogen, Inc. to Present at the Goldman, Sachs & Co. Healthcare CEOs Unscripted Conference 12/29/2011 5:56:48 AM    More...
Biogen, Inc. Reports Third Quarter 2011 Results 10/28/2011 7:40:00 AM    More...
123456

//-->